<DOC>
	<DOCNO>NCT00721227</DOCNO>
	<brief_summary>This trial ass feasibility reduction gastroplasty standard suture bariatric patient candidate surgical weight loss intervention .</brief_summary>
	<brief_title>Assessment Gastric Volume Reduction Surgical Weight Loss Candidates</brief_title>
	<detailed_description>The overall plan subject consist follow element : - Subject informed nature research , give Informed Consent Document ( ICD ) read , subject understands agree procedure ask sign write informed consent ( ICD ) . - Subjects undergo reduction gastroplasty gastric plication section stomach infolded multiple row suture . - Subjects follow 12 month evaluate outcome potential complication .</detailed_description>
	<mesh_term>Weight Loss</mesh_term>
	<criteria>Subjects consider appropriate candidate study fulfill follow criterion : 1 . Subject willing give consent comply evaluation treatment schedule ; 2 . 21 60 year age ( inclusive ) ; 3 . BMI &gt; 35 kg/m2 &lt; 50 kg/m2 ( BMI 3540 kg/m2 allowable one significant medical condition relate obesity , include comorbid condition hyperlipidemia , mild obstructive sleep apnea ( per Investigators discretion ) , hypertension , osteoarthritis hip knee per investigational site 's criterion subject treat , generally expect improve , reverse , resolve weight loss ) ; 4 . Candidate surgical weight loss intervention ( i.e. , meet ASMBS24 NIH criterion ) ; 5 . Absence significant psychopathology could limit subject 's ability understand procedure , comply medical , surgical , and/or behavioral recommendation , per site standard care ( SOC ) ; 6 . Agree refrain type elective procedure would affect body weight abdominal lipoplasty liposuction , mammoplasty , removal excess skin duration trial . Subjects exclude study follow : 1 . Women childbearing potential pregnant lactating time screen time surgery ; 2 . Documented history drug and/or alcohol abuse within two ( 2 ) year Screening Visit ; 3 . Previous malabsorptive restrictive procedure perform treatment obesity ; 4 . Scheduled concurrent surgical procedure ; 5 . Participation investigational device drug study ( non survey base trial ) within 12 week enrollment ; 6 . Any condition precludes compliance study , include : 1 . Inflammatory disease gastrointestinal tract , include severe intractable esophagitis , gastric ulceration , duodenal ulceration , specific inflammation Crohn 's disease ulcerative colitis active within past 10 year ; 2 . Congenital acquire anomaly GI tract , include atresias stenosis ; 3 . Severe cardiopulmonary disease serious organic disease make subject highrisk surgical candidate ; 4 . Uncontrolled hypertension ; 5 . Portal hypertension ; 6 . Treatment insulin ( 50 unit day ) ; 7 . Chronic acute upper gastrointestinal bleeding condition ( e.g. , gastric esophageal varix ) ; 8 . Cirrhosis ; 9 . Congenital acquire intestinal telangiectasia ; 10 . Esophageal gastric disorder include moderate severe preoperative reflux , dysmotility , Barrett 's esophagus ; 11 . Presence hiatal hernia ; 12 . Prior surgery foregut include hiatal hernia repair prior gastric surgery ; 13 . Pancreatitis ; 14 . Immunocompromised result chronic oral steroid use , chemotherapeutic agent , immune deficiency disorder ; 15 . Conditions , opinion investigator , may jeopardize subject 's wellbeing and/or soundness clinical study ; 7 . History presence preexist autoimmune connective tissue disease ; 8 . Use prescription counter weight reduction medication supplement within thirty day Screening Visit duration study participation .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>